Metabolomics in the context of systems biology: Bridging Traditional Chinese Medicine and molecular pharmacology

Phytotherapy Research

Volumn 19, Issue 3, 2005, Pages 173-182

  Wang, Mei ^a,b   Lamers, Robert Jan A N ^b,c   Korthout, Henrie A A J ^b   Van Nesselrooij, Joop H J ^b   Witkamp, Renger F ^b   Van Der Heijden, Rob ^c   Voshol, Peter J ^b   Havekes, Louis M ^b   Verpoorte, Rob ^c   Van Der Greef, Jan ^a,b,c  

^a SU BioMedicine   (Netherlands)

^b TNO   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Metabolomics; Systems biology; Traditional Chinese Medicine (TCM)

Indexed keywords

5' METHOXYHDNOCARPIN; ALANINE AMINOTRANSFERASE; ALKALOID; APOLIPOPROTEIN E; BERBERINE; BIFLAVONOID; BILOBALIDE; CANNABIDIOL; CANNABIS; CHACONINE; CHOLESTEROL; FLAVONOID; GINKGO BILOBA EXTRACT; GINKGOLIDE; GLUCOSIDE; HERBACEOUS AGENT; INSULIN; LOW DENSITY LIPOPROTEIN; PLANT EXTRACT; PRODRUG; SALICYLIC ACID; SALIGENIN; SAPONIN; SOLANINE; TETRAHYDROCANNABINOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; BARK; BLOOD FLOW; CHINESE MEDICINE; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; DATA ANALYSIS; DNA MICROARRAY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; FEMALE; GINKGO BILOBA; HEADACHE; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; INSULIN SENSITIVITY; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; LIPID METABOLISM; LIVER FUNCTION; MALE; MASS SPECTROMETRY; MEDICINAL PLANT; METABOLIC SYNDROME X; METABOLITE; METABOLOMICS; MOLECULAR PHARMACOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PAIN; PHYTOTHERAPY; PLANT LEAF; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REVIEW; THIN LAYER CHROMATOGRAPHY; TRADITIONAL MEDICINE; WILLOW;

DRUGS, CHINESE HERBAL; HUMANS; PHARMACOLOGY; PHYTOTHERAPY;

EID: 20444478277     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1624     Document Type: Review

References (37)

1. Alaoui-Youssefi A, Lamproglou I, Drieu K, Emerit I. 1999. Anticlastogenic effects of Ginkgo biloba extract (EGb 761) and some of its constituents in irradiated rats. Mutat Res 445: 99-104.
2. Boelsma E, Lamers R-JAN, Hendriks HFJ, van Nesselrooij JHJ, Roza L. 2004. Changes in skin blood flow after Ginkgo biloba supplementation are accompanied by differences in urinary metabolites. Planta Med. 70: 1052-1057.
3. Carlini EA, Karniol IG, Renault PF, Schuster CR. 1974. Effects of marihuana in laboratory animals and in man. Br J, Pharmacol 50: 299-309.
4. Clish CB, Davidov E, Oresic M, et al. 2004. Systems biology analysis of the ApoE3-Leiden transgenic mouse. OMICS 1: 3-13.
5. Cheng J-T. 2000. Review: Drug therapy in Chinese traditional medicine. J Clin Pharmacol 40: 445-450.
6. Curtis PP, Vere D, Fray P. 1999. Therapeutic value of Ginkgo biloba in reducing symptoms of decline in mental function. J Pharm Pharmacol 51: 535-541.
7. Duivenvoorden I, Teusink B, Rensen PCN, Romijn JA, Havekes LM, Voshol PJ. 2005. Apolipoprotein C3-deficiency results in diet-induced obesity and insulin resistance in mice. Diabetes. 54: 664-671.
8. Fontanarosa PB, Lundberg GD. 1998. Alternative medicine meets science. JAMA 280: 1618-1619.
9. 't Hart BA, Vogels JTWE, Spijksma G, Brok HPM, Polman C, Van der Greef J. 2003. H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. J Neurol Sci 212: 21-30.
10. Jack DB. 1997. One hundred years of aspirin. Lancet 350: 437-439.
11. Jong MC, Voshol PJ, Muurling M, et al. 2001. Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein CI. Diabetes 50: 2779-2785.
12. Lamers R-JAN, DeGroot J, Spies-Faber EJ, et al. 2003a. Identification of disease and nutrient related metabolic fingerprints in osteoarthritic guinea pigs. J Nutr 133: 1776-1780.
13. Lamers R-JAN, Wessels ECH, Van de Sandt JJM, et al. 2003b. A pilot study to investigate effects of inulin on Caco-2 cells through in-vitro metabolic fingerprinting. J Nutr 133: 3080-3084.
14. Malone MH, Robichaud RC. 1962. A Hippocratic screen for pure or crude drug materials. Lloydla 25: 320-331.
15. Mechoulam R. 1972. Cannabis and its Derivatives, Crawn J, Paton WDM (eds). Oxford University Press: London, 1-13.
16. Morel NM, Holland JM, Van der Greef J, et al. 2004. Primer on medical genomics, Part XIV: Introduction to systems biology-a new approach to understanding disease and treatment. Mayo Clinic Proc 77: 651-659.
17. Muurling M, Jong MC, Mensink RP, et al. 2002. A low-fat diet has a higher potential than energy restriction to improve high-fat diet-induced insulin resistance in mice. Metabolism 51: 695-701.
18. Patwardhan B, Vaidya ADB, Chorghade M. 2004. Ayurveda and natural products drug discovery. Curr Sci 86: 789-799.
19. Roddick JM, Rijnenberg AL. 1987. Synergistic interaction between potato glycoalkaloids α-solanine and α-chaconine in relation to lysis of phospholipids/sterol liposomes. Phytochemistry 26: 1325-1328.
20. Roddick JG, Rijnenberg AL, Osman SF. 1988. Synergistic interaction between potato glycoalkaloids α-solanine and α-chaconine in relation to destabilisation of cell membranes: ecological implications. J Chem Ecol 14: 889-902.
21. Roddick JG, Rijnenberg AL, Weissenberg M. 1990. Membrane-disrupting properties of the steroidal glycoalkaloids solasonine and solamargine. Phytochemistry 29: 1513-1518.
22. Roy S, Kobuchi H, Sen CK, Gohil K, DroyLefaix MT, Packer L. 1998. Ginkgo biloba extract (EGb 761): antioxidant properties and regulation of gene expression. Ginkgo biloba extract EGb 761 lessons from cell biology 7: 1-17.
23. Scholten WK. 2003. The new European Union Good Agricultural and Collection Practice rules: Is good x practice good enough if it does not result in batch-to-batch consistency. Drug Inform J 37: 321-327.
24. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. 2000. Synergy in a medicinal plant:antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 97: 1433-1437.
25. Sumner LW, Mendes P, Dixon RA. 2003. Plant metabolomics: large-scale phytochemistry in the functional genomic era. Phytochemistry 62: 817-836.
26. Talalay P, Talalay P. 2001. The importance of using scientific principles in the development of medicinal agents from plants. Acad Med 76: 228-247.
27. Udani J. 1998. Integrating alternative medicine into practice. JAMA 280: 1620.
28. 3-36 reinforces insulin action on glucose disposal in mice fed a high fat diet. Diabetes 53: 1949-1952.
29. Van der Greef J, Davidov E, Verheij E, et al. 2002. The role of metabolomics in Systems Biology, a new vision for drug discovery and development. In Metabolic Profiling: Its Role in Biomarker Discovery and Gene Function Analysis, Harrigan GG, Goodacre R (eds). Kluwer Academic: Boston MA, USA, 170-198.
30. Van der Greef J, van der Heijden R, Verheij ER. 2004. The role of mass spectrometry in systems biology: data processing and identification strategies in metabolomics. In Advances in Mass Spectrometry, Volume 16, Ashcroft AE, Brenton G, Monaghan JJ (eds). Elsevier Science: Amsterdam, 145-165.
31. Van Vlijmen BJM, van 't Hof HB, Mol MJTM, et al. 1996. Modulation of very low density lipoprotein production and clearance contributes to age and gender dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 97: 1184-1192.
32. Verpoorte R, Van der Hijden R, Hoopen HJG, Memelink J. 1999. Metabolic engineering of plant secondary metabolite pathways for the production of fine chemicals. Biotechnol Lett 21: 467-479.
33. Voshol PJ, Jong MC, Dahlmans VEH, et al. 2001. In muscle-specific LPL overexpression mice muscle triglyceride content is increased, without inhibition of insulin-stimulated whole body and muscle specific glucose uptake. Diabetes 50: 2585-2590.
34. Wang Y, Tang H, Nicholson JK, et al. 2004. Related articles, links metabolomic strategy for the classification and quality control of phytomedicine: a case study of chamomile flower (Matricaria recutita L.). Planta Med 70: 250-255.
35. Williamson EM, Evans FJ. 2000. Cannabis in clinical practice. Drugs 60: 1303-1314.
36. Williamson EM, Whalley BJ. 2002. Cannabis as a medicine: evidence for synergy. 26th LOF Symposium 15 February 2002, Leiden, abstract book page Leiden University Press 7-8: Leiden, Netherlands.
37. Yuan R, Lin Y. 2000. Traditional Chinese Medicine: an approach to scientific proof and clinical validation. Pharmacol Ther 86: 191-198.